Improved immune status corresponds with long-term decline of quantitative serum hepatitis B surface antigen in HBV/HIV co-infected patients

Viral Immunology

Volumn 25, Issue 6, 2012, Pages 442-447

  Arendt, Eduard ^a   Jaroszewicz, Jerzy ^a,b   Rockstroh, Jürgen ^c   Meyer Olson, Dirk ^a   Zacher, Behrend J ^a   Mederacke, Ingmar ^a   Manns, Michael P ^a   Wedemeyer, Heiner ^a   Cornberg, Markus ^a   Wursthorn, Karsten ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VIRUS DNA; VIRUS RNA;

ADOLESCENT; ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PROTEIN BLOOD LEVEL; VIRUS LOAD; VIRUS REPLICATION;

ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DNA, VIRAL; DRUG MONITORING; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; RETROSPECTIVE STUDIES; RNA, VIRAL; SERUM; TREATMENT OUTCOME; VIRAL LOAD;

HEPATITIS B VIRUS;

EID: 84871085565     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2012.0036     Document Type: Article

References (26)

1. European AIDS Clinical Society: T. E. A. C. S. EACS Guidelines Version 6, October 2011, p. 61.
2. Alter MJ: Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006;44:S6-S9. (Pubitemid 43053865)
3. Bodsworth NJ, Cooper DA, and Donovan B: The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991;163:1138-1140.
4. Brunetto MR, Moriconi F, Bonino F, et al.: Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009;49:1141-1150.
5. Grandvaux N, tenOever BR, Servant MJ, and Hiscott J: The interferon antiviral response: from viral invasion to evasion. Curr Opin Infect Dis 2002;15:259-267. (Pubitemid 34548188)
6. Heathcote EJ, Marcellin P, Buti M, et al.: Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2010;140:132-143.
7. Iser DM, Avihingsanon A, Wisedopas N, et al.: Increased intrahepatic apoptosis but reduced immune activation in HIV-HBV co-infected patients with advanced immunosuppression. AIDS 2011;25:197-205.
8. Jaroszewicz J, Calle Serrano B, Wursthorn K, et al.: Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010;52:514-522.
9. Jaroszewicz J, Ho H, Markova A, et al.: Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues. Antiviral Ther 2011;16:915-924.
10. Kourtis AP, Bulterys M, Hu DJ, and Jamieson DJ: HIV-HBV coinfection-a global challenge. N Engl J Med 2012;366: 1749-1752.
11. Lacombe K, Bottero J, Lemoine M, Boyd A, and Girard PM: HIV/hepatitis B virus co-infection: current challenges and new strategies. J Antimicrob Chemother 2009;65:10-17.
12. Landrum ML, Fieberg AM, Chun HM, et al.: The effect of human immunodeficiency virus on hepatitis B virus serologic status in co-infected adults. PLoS One 2010; 5:e8687.
13. Mallet VO, Dhalluin-Venier V, Verkarre V, et al.: Reversibility of cirrhosis in HIV/HBV coinfection. Antiviral Ther 2007;12:279-283. (Pubitemid 46569914)
14. Maylin S, Boyd A, Lavocat F, et al.: Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIVhepatitis B virus-infected patients. AIDS 2012;26:939-949.
15. Miailhes P, Trabaud MA, Pradat P, et al.: Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. Clin Infect Dis 2007;45:624-632. (Pubitemid 47328645)
16. Panel, o. A. G. f. A. a. A.: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. D. o. H. a. H. Services, ed. 2011;1-166.
17. Reijnders JG, Rijckborst V, Sonneveld MJ, et al.: Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol 2010;54:449-454.
18. Rijckborst V, Hansen BE, Cakaloglu Y, et al.: Early ontreatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010;52:454-461.
19. Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, and Janssen HL: Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010;52:1251-1257.
20. Soriano V, Mocroft A, Peters L, et al.: Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. J Antimicrob Chemother 2010; 65:548-555.
21. Thibault V, Stitou H, Desire N, Valantin MA, Tubiana R, and Katlama C: Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients. Antiviral Ther 2011; 16:199-205.
22. Thio CL: Hepatitis B and human immunodeficiency virus coinfection. Hepatology 2009;49:S138-S145.
23. Thompson AJ, Nguyen T, Iser D, et al.: Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010;51:1933-1944.
24. World Health Organization: Hepatitis B, 2011.
25. Wursthorn K, Jung M, Riva A, et al.: Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010;52:1611-1620.
26. Wursthorn K,Wedemeyer H, andMannsMP:Managing HBV in patients with impaired immunity. Gut 2010;59:1430-1445.